FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225299135> ?p ?o ?g. }

• W4225299135 endingPage "e202" @default.
• W4225299135 startingPage "e193" @default.
• W4225299135 abstract "BackgroundSafe and effective vaccines are urgently needed to end the COVID-19 pandemic caused by SARS-CoV-2 infection. We aimed to assess the preliminary safety, tolerability, and immunogenicity of an mRNA vaccine ARCoV, which encodes the SARS-CoV-2 spike protein receptor-binding domain (RBD).MethodsThis single centre, double-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial of ARCoV was conducted at Shulan (Hangzhou) hospital in Hangzhou, Zhejiang province, China. Healthy adults aged 18–59 years negative for SARS-CoV-2 infection were enrolled and randomly assigned using block randomisation to receive an intramuscular injection of vaccine or placebo. Vaccine doses were 5 μg, 10 μg, 15 μg, 20 μg, and 25 μg. The first six participants in each block were sentinels and along with the remaining 18 participants, were randomly assigned to groups (5:1). In block 1 sentinels were given the lowest vaccine dose and after a 4-day observation with confirmed safety analyses, the remaining 18 participants in the same dose group proceeded and sentinels in block 2 were given their first administration on a two-dose schedule, 28 days apart. All participants, investigators, and staff doing laboratory analyses were masked to treatment allocation. Humoral responses were assessed by measuring anti-SARS-CoV-2 RBD IgG using a standardised ELISA and neutralising antibodies using pseudovirus-based and live SARS-CoV-2 neutralisation assays. SARS-CoV-2 RBD-specific T-cell responses, including IFN-γ and IL-2 production, were assessed using an enzyme-linked immunospot (ELISpot) assay. The primary outcome for safety was incidence of adverse events or adverse reactions within 60 min, and at days 7, 14, and 28 after each vaccine dose. The secondary safety outcome was abnormal changes detected by laboratory tests at days 1, 4, 7, and 28 after each vaccine dose. For immunogenicity, the secondary outcome was humoral immune responses: titres of neutralising antibodies to live SARS-CoV-2, neutralising antibodies to pseudovirus, and RBD-specific IgG at baseline and 28 days after first vaccination and at days 7, 15, and 28 after second vaccination. The exploratory outcome was SARS-CoV-2-specific T-cell responses at 7 days after the first vaccination and at days 7 and 15 after the second vaccination. This trial is registered with www.chictr.org.cn (ChiCTR2000039212).FindingsBetween Oct 30 and Dec 2, 2020, 230 individuals were screened and 120 eligible participants were randomly assigned to receive five-dose levels of ARCoV or a placebo (20 per group). All participants received the first vaccination and 118 received the second dose. No serious adverse events were reported within 56 days after vaccination and the majority of adverse events were mild or moderate. Fever was the most common systemic adverse reaction (one [5%] of 20 in the 5 μg group, 13 [65%] of 20 in the 10 μg group, 17 [85%] of 20 in the 15 μg group, 19 [95%] of 20 in the 20 μg group, 16 [100%] of 16 in the 25 μg group; p<0·0001). The incidence of grade 3 systemic adverse events were none (0%) of 20 in the 5 μg group, three (15%) of 20 in the 10 μg group, six (30%) of 20 in the 15 μg group, seven (35%) of 20 in the 20 μg group, five (31%) of 16 in the 25 μg group, and none (0%) of 20 in the placebo group (p=0·0013). As expected, the majority of fever resolved in the first 2 days after vaccination for all groups. The incidence of solicited systemic adverse events was similar after administration of ARCoV as a first or second vaccination. Humoral immune responses including anti-RBD IgG and neutralising antibodies increased significantly 7 days after the second dose and peaked between 14 and 28 days thereafter. Specific T-cell response peaked between 7 and 14 days after full vaccination. 15 μg induced the highest titre of neutralising antibodies, which was about twofold more than the antibody titre of convalescent patients with COVID-19.InterpretationARCoV was safe and well tolerated at all five doses. The acceptable safety profile, together with the induction of strong humoral and cellular immune responses, support further clinical testing of ARCoV at a large scale.FundingNational Key Research and Development Project of China, Academy of Medical Sciences China, National Natural Science Foundation China, and Chinese Academy of Medical Sciences." @default.
• W4225299135 created "2022-05-05" @default.
• W4225299135 creator A5000309922 @default.
• W4225299135 creator A5001251985 @default.
• W4225299135 creator A5003546267 @default.
• W4225299135 creator A5005073493 @default.
• W4225299135 creator A5005132315 @default.
• W4225299135 creator A5008178802 @default.
• W4225299135 creator A5010701166 @default.
• W4225299135 creator A5014810814 @default.
• W4225299135 creator A5015105154 @default.
• W4225299135 creator A5019018136 @default.
• W4225299135 creator A5020191359 @default.
• W4225299135 creator A5043569952 @default.
• W4225299135 creator A5049503333 @default.
• W4225299135 creator A5051200107 @default.
• W4225299135 creator A5057422995 @default.
• W4225299135 creator A5060722524 @default.
• W4225299135 creator A5062907814 @default.
• W4225299135 creator A5069618896 @default.
• W4225299135 creator A5071212122 @default.
• W4225299135 creator A5072550037 @default.
• W4225299135 creator A5075716007 @default.
• W4225299135 creator A5076320154 @default.
• W4225299135 creator A5077569532 @default.
• W4225299135 creator A5080443939 @default.
• W4225299135 creator A5080874179 @default.
• W4225299135 creator A5080902896 @default.
• W4225299135 creator A5082036476 @default.
• W4225299135 creator A5082421105 @default.
• W4225299135 creator A5083375648 @default.
• W4225299135 creator A5083548222 @default.
• W4225299135 creator A5086243720 @default.
• W4225299135 date "2022-03-01" @default.
• W4225299135 modified "2023-10-07" @default.
• W4225299135 title "Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial" @default.
• W4225299135 cites W2047882003 @default.
• W4225299135 cites W2087802416 @default.
• W4225299135 cites W2292472819 @default.
• W4225299135 cites W2912850482 @default.
• W4225299135 cites W2915991550 @default.
• W4225299135 cites W2983736730 @default.
• W4225299135 cites W2986812831 @default.
• W4225299135 cites W3001465255 @default.
• W4225299135 cites W3001897055 @default.
• W4225299135 cites W3012650581 @default.
• W4225299135 cites W3016350657 @default.
• W4225299135 cites W3023230016 @default.
• W4225299135 cites W3024643080 @default.
• W4225299135 cites W3027138240 @default.
• W4225299135 cites W3034680516 @default.
• W4225299135 cites W3042833857 @default.
• W4225299135 cites W3043722389 @default.
• W4225299135 cites W3043991892 @default.
• W4225299135 cites W3046194290 @default.
• W4225299135 cites W3046985131 @default.
• W4225299135 cites W3048620154 @default.
• W4225299135 cites W3048775784 @default.
• W4225299135 cites W3082164758 @default.
• W4225299135 cites W3083217488 @default.
• W4225299135 cites W3093367571 @default.
• W4225299135 cites W3107730772 @default.
• W4225299135 cites W3111255098 @default.
• W4225299135 cites W3128961456 @default.
• W4225299135 cites W3154648093 @default.
• W4225299135 cites W3163785571 @default.
• W4225299135 cites W4205483821 @default.
• W4225299135 doi "https://doi.org/10.1016/s2666-5247(21)00280-9" @default.
• W4225299135 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35098177" @default.
• W4225299135 hasPublicationYear "2022" @default.
• W4225299135 type Work @default.
• W4225299135 citedByCount "30" @default.
• W4225299135 countsByYear W42252991352022 @default.
• W4225299135 countsByYear W42252991352023 @default.
• W4225299135 crossrefType "journal-article" @default.
• W4225299135 hasAuthorship W4225299135A5000309922 @default.
• W4225299135 hasAuthorship W4225299135A5001251985 @default.
• W4225299135 hasAuthorship W4225299135A5003546267 @default.
• W4225299135 hasAuthorship W4225299135A5005073493 @default.
• W4225299135 hasAuthorship W4225299135A5005132315 @default.
• W4225299135 hasAuthorship W4225299135A5008178802 @default.
• W4225299135 hasAuthorship W4225299135A5010701166 @default.
• W4225299135 hasAuthorship W4225299135A5014810814 @default.
• W4225299135 hasAuthorship W4225299135A5015105154 @default.
• W4225299135 hasAuthorship W4225299135A5019018136 @default.
• W4225299135 hasAuthorship W4225299135A5020191359 @default.
• W4225299135 hasAuthorship W4225299135A5043569952 @default.
• W4225299135 hasAuthorship W4225299135A5049503333 @default.
• W4225299135 hasAuthorship W4225299135A5051200107 @default.
• W4225299135 hasAuthorship W4225299135A5057422995 @default.
• W4225299135 hasAuthorship W4225299135A5060722524 @default.
• W4225299135 hasAuthorship W4225299135A5062907814 @default.
• W4225299135 hasAuthorship W4225299135A5069618896 @default.
• W4225299135 hasAuthorship W4225299135A5071212122 @default.
• W4225299135 hasAuthorship W4225299135A5072550037 @default.
• W4225299135 hasAuthorship W4225299135A5075716007 @default.
• W4225299135 hasAuthorship W4225299135A5076320154 @default.
• W4225299135 hasAuthorship W4225299135A5077569532 @default.

• next